Clinical trial
Paclitaxel in Treating Patients With Ovarian Stromal Cancer
NCT00006227 · Gynecologic Oncology Group, Other · Completed
Key facts
| NCT number | NCT00006227 |
|---|---|
| Title | Paclitaxel in Treating Patients With Ovarian Stromal Cancer |
| Official title | Phase II Study of Paclitaxel for Ovarian Stromal Tumors as Second-Line Therapy |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Type Ovarian Granulosa Cell Tumor, Ovarian Gynandroblastoma, Ovarian Sertoli-Leydig Cell Tumor, Ovarian Sex Cord Tumor With Annular Tubules, Ovarian Steroid Cell Tumor |
| Intervention type | Drug |
| Interventions | Paclitaxel |
| Enrollment | 31 |
| Start date | Nov 20, 2000 |
| Primary completion | Jul 16, 2016 |
| Completion | Jul 16, 2016 |
| First posted | Jan 27, 2003 |
| Last update posted | Mar 5, 2020 |
| Countries | Japan, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: